Celgene Recommends Shareholders Reject "Mini-Tender" Offer by TRC Capital Corporation
Celgene Recommends Shareholders Reject Mini-Tender Offer by TRC Capital Corporation
Celgene, BioMarin and Vertex are RBC's Top Biotech Buys
Celgene Hits 52-Week High on Positive CHMP Opinion
IBD 50 Index Still Lags, But Some Stocks Find Mojo
Newly Profitable Medivation Riding High On Drug Sales
Quick Look at the Lg Cap All Time Highs...
Cramer: Not too late to buy Regeneron
Celgene's PDE4 Inhibitor Otezla Gets Positive CHMP Opinion
Nasdaq Climbs, But AT&T, Verizon, Drag Dow Down
Chip Stocks, Biotechs Lead Another Nasdaq Rally
5 Trade Ideas for Celgene this Week
Alibaba Among 5 Top Stocks With Top Profit Margins
Cramer: Stick with what's working
AbbVie, Celgene, Sanofi Drugs Get EU Endorsements
Trade-Ideas: Celgene (CELG) Is Today's Momo Momentum Stock
Celgene Receives Positive CHMP Opinion for OTEZLA (apremilast), the First Oral PDE4 Inhibitor for the Treatment of Patients with Psoriasis and Psoriatic Arthritis
Europe gives green light to AbbVie hepatitis C medicine, others
Celgene Receives Positive CHMP Opinion for OTEZLA (apremilast), the First Oral PDE4 Inhibitor for the Treatment of Patients with Psoriasis and Psoriatic Arthritis
Chef Michael Ferraro, the Pancreatic Cancer Action Network and Meals to Heal Team up with Celgene to Address Nutritional Needs and Challenges Faced by Pancreatic Cancer Patients and Caregivers
Celgene Up on Encouraging Long-Term Phase III Otezla Data
Cramer shares hazards of skepticism
Oral OTEZLA (Apremilast) Showed Sustained Clinical Response over Two Years in Patients with Active Psoriatic Arthritis
UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Increases CD4 Counts in People Living With HIV
Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4 Counts in People Living With HIV
Global Survey Finds That Pancreatic Cancer, a Leading Cause of Cancer Deaths, is Virtually Unknown by Many in Europe and US
Celgene Corporation to Webcast at Upcoming Investor Conferences and Medical Congress
Acceleron Collaboration Partner Celgene to Present Data at the American Society of Nephrology Kidney Week 2014
Celgene beats Street 3Q forecasts
Phase II Data in Crohn's Disease for Celgene's Oral Antisense Therapy GED-0301 to Be Presented at UEG Week 2014
Celgene Reports First Quarter 2014 Operating and Financial Results
Drug firm exec gets 16 months in inside-trade case
Acceleron, Celgene and Collaborators Announce Two Publications in Nature Medicine Describing Sotatercept and ACE-536 Therapeutic Potential in Beta-thalassemia and Myelodysplastic Syndromes
FDA approves specialty arthritis drug from Celgene
Celgene Reiterates Commitment to Improving Pancreatic Cancer Care in Europe, Through Significant Research and Patient Support Initiatives
Acceleron and Celgene Announce Interim Clinical Data for Sotatercept in Patients with End Stage Renal Disease on Hemodialysis at the 2014 National Kidney Foundation Spring Clinical Meeting
Celgene Corporation Board of Directors Recommends to Our Stockholders a Two-for-One Stock Split
Celgene Corporation to Present at Investor Conferences in February and March
World Cancer Day: A Single Day Is Never Enough
Celgene Reports Fourth Quarter and Full Year 2013 Operating and Financial Results
Celgene Corporation to Announce Fourth Quarter and Full Year 2013 Results on January 30, 2014
Regeneron slips after getting a boost from outlook
Celgene Corporation Announces 2014 Financial Outlook and Preliminary 2013 Results
Celgene cuts 4Q, 2013 adj. profit outlooks
Celgene Corporation to Present 2013 Unaudited Financial Results and Updated Financial Outlook at the 32nd Annual J.P. Morgan Healthcare Conference
EU clears Celgene's Abraxane for pancreatic cancer
ABRAXANE Plus gemcitabine Receives European Marketing Authorization for First-Line Treatment of Patients with Metastatic Pancreatic Cancer
Celgene Corporation to Present at the 32nd Annual J.P. Morgan Healthcare Conference
REVLIMID (lenalidomide)-Treated Patients with Deletion-5q MDS Who Achieve Transfusion-Independence of At Least 26 Weeks and AML-Free Survival Associated with Cytogenetic Response
OncoMed stock doubles after cancer drug deal with Celgene
Why Celgene Corporation Stock Rocketed 13% Higher in October
Today Celgene (CELG) Hits New Lifetime High
Celgene Stock Price: Is It Bubbly?
5 Things Celgene Corporation's Management Wants You to Know
ModernGraham Quarterly Valuation Of Celgene Corporation (CELG)
Celgene Corporation: Celgene Recommends Shareholders Reject &quot;Mini-Tender ...
Trade of the Day: Buy CELG Stock Now or Wait for a Pullback?
Stock of the Week: Celgene Corp. (CELG)
Trade of the Day: Celgene (CELG) Stock is a Stellar Buy at $100
Celgene Is Up 22% Over The Past Month; What Do Technicians Think?
